Latest news in cancer
World-first lung cancer vaccine trials started in seven countries
The lung cancer vaccine clinical trial had been recently launched in seven countries, including the United States, Japan, and Spain, which could prove to be an...
Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer
August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with...
Neoadjuvant/adjuvant durvalumab is approved by the USFDA for resectable non-small cell lung cancer
The USFDA approved neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable NSCLC. It marked a turning point in cancer treatment by...
The FDA has granted approval for the use of vorasidenib in the treatment of Grade 2 astrocytoma or oligodendroglioma in patients having a specific IDH1 or IDH2 mutation
The FDA has granted approval for the use of vorasidenib in treating Grade 2 astrocytoma or oligodendroglioma in patients with a specific IDH1 or IDH2 mutation....
The FDA has granted accelerated approval to afamitresgene autoleucel for the treatment of unresectable or metastatic synovial sarcoma
The FDA has granted accelerated approval to afamitresgene autoleucel, a CAR T-cell therapy, for the treatment of unresectable or metastatic synovial sarcoma in...
The FDA has broadened the indication for dostarlimab-gxly to include the treatment of endometrial cancer in combination with chemotherapy
Dostarlimab-gxly is now indicated for the treatment of endometrial cancer in association with chemotherapy. The broader indication provides that it will be...
The FDA has granted approval for the use of daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of multiple myeloma
The FDA has granted approval for the utilization of daratumumab and hyaluronidase-fihj in conjunction with bortezomib, lenalidomide, and dexamethasone as a...
The FDA has granted expedited approval to epcoritamab-bysp for the treatment of R/R follicular lymphoma
Epcoritamab-bysp has received accelerated approval from the FDA for the treatment of relapsed or refractory (R/R) follicular lymphoma, a subtype of non-Hodgkin...
CAR T Cell Therapy for Blood Cancers
CAR T-cell therapy represents a new frontier of treatment against blood cancers, like leukemia and lymphoma. In this brand-new treatment, the T-cells are...
The FDA Approved The First Engineered T Cell Therapy for Solid Tumors
The FDA just approved the first engineered T cell therapy for solid tumors, signaling a significant advancement in cancer treatment. This new therapy uses...
CAR T Cell Therapy for Relapsed and Refractory Cancers
It is also an innovative treatment for the relapsed or refractory cancers. Treatment involves genetic modification of a patient's T cells to express chimeric...
CAR T Cell Therapy for Pediatric Cancer
Introduction Although relatively rare, pediatric malignancy is one of the leading causes of mortality in children worldwide. Even though traditional therapies...
CAR T Cell Therapy for Solid Tumors
CAR T cell therapy has moved from its original effective blood cancers to solid tumors. Herein, a patient's modified T cells are made to express chimeric...
CAR T-Cell therapy for lymphoma
Introduction CAR T cell therapy has been a game-changer in the treatment of certain lymphomas, more so in patients relapsing or refractory to conventional...
CAR T-Cell therapy for leukemia
Introduction CAR T cell therapy is the breakthrough treatment against various kinds of leukemias, particularly B-cell ALL. In this treatment, genetically...
Types of cancer treated with CAR T-Cell therapy
Introduction CAR T cell therapy has really taken off in harnessing the immune system to specifically destroy cancerous cells. After showing tremendous success...
Complete mechanism of CAR T Cell therapy explained
CAR T cell production involves several key steps. Initially, T cells are isolated from a patient's blood (autologous) or from a healthy donor (allogeneic)....
Gamma delta T cells: Latest option in cancer treatment
Two types of T-cells There exist two distinct categories of T cells: αβ T cells and γδ T cells. The previous statement describes a T-cell receptor (TCR)...
Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively...
Disruption of CD5 on CAR T Cells Enhances the Effectiveness of Anti-Tumor Treatment
CAR T-Cell therapy in the treatment of cancer A preclinical study conducted by researchers at the University of Pennsylvania’s Perelman School of...
The future of gene therapy: What to expect in the next decade?
Gene therapy Gene therapy, which means changing genes to cure or avert diseases, has progressed significantly in the last number of years. The future of gene...
Unlocking the genetic code: The future of gene therapy for genetic disorders
Gene therapy has typified the revolution in medicine that gives hope to various genetic disorders. This advanced treatment stops, and sometimes even reverses,...
CRISPR and gene editing: Revolutionizing gene therapy
This makes the CRISPR-Cas9 technology one of the most potent tools known in gene therapy for very accurate, efficient, and versatile genome editing; it has...
Gene therapy in treating cancer: Success stories and challenges
Gene therapy is shifting concepts in cancer treatments from genes to boosting immune responses. The success stories are CAR-T cell therapies like Kymriah...
The history and evolution of gene therapy
Gene therapy has truly traveled a distance—from its conceptual roots dating back to the mid-20th century to its modern claim to fame with CRISPR technology....
Gene therapy in China
Gene therapy in China is rapidly advancing because of massive investment in research and development. Equipped with state-of-the-art technology, such as...
First Gene Therapy for Children with Metachromatic Leukodystrophy is Approved by the FDA
FDA approval The U.S. Food and Drug Administration has granted Lenmeldy (atidarsagene autotemcel) approval. The FDA has approved this gene therapy as the first...
FDA approves gene therapy to treat beta thalassemia
The FDA has approved a groundbreaking gene therapy to treat beta thalassemia, a genetic blood disorder that requires regular blood transfusions. This...
First gene therapy approved by the USFDA to treat sickle cell disease
USFDA approved gene therapy for sickle cell disease The U.S. Food and Drug Administration has granted approval for two significant medications, Casgevy and...
Gene Therapy for Thalassemia
Gene therapy for thalassemia is a groundbreaking treatment that targets the genetic roots of the disease. By introducing functional copies of the beta-globin...
Gene therapy for sickle cell anemia
Gene therapy for sickle cell anemia offers a promising solution by targeting the root cause of the disease. This innovative treatment involves modifying the...
CAR T-Cell therapy for Chronic Lymphocytic Leukemia
Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become...
Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on...
Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on...
Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer
The USFDA has approved Durvalumab combined with chemotherapy for treating mismatch repair-deficient primary advanced or recurrent endometrial cancer. This...
Repotrectinib has received accelerated approval from the USFDA for adult and pediatric patients with NTRK gene fusion-positive solid tumors
Repotrectinib has received accelerated approval for treating adult and pediatric patients with NTRK gene fusion-positive solid tumors. This approval, based on...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.